Growth & profitability
- Revenue has grown 2.9% per year over the past 5 years.
- Operating margin has contracted, at -891.1% in the latest year.
KYMR Financials Kymera Therapeutics, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $39M | $311M | 0.0% | -891.1% | -$234M | — | $357M |
| 2024 | $47M | $224M | 0.0% | -555.8% | -$207M | — | $120M |
| 2023 | $79M | $147M | 0.0% | -210.6% | -$137M | — | $110M |
| 2022 | $47M | $155M | 0.0% | -344.4% | -$156M | — | $68M |
| 2021 | $73M | $100M | 0.0% | -138.0% | -$131M | — | $48M |
| 2020 | $34M | -$46M | 0.0% | -136.1% | $79M | — | $31M |
| 2019 | $3M | -$41M | 0.0% | -1438.5% | $17M | — | $76M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $34M | -$69M | 0.0% | -244.9% | -$89M | — | $144M |
| Dec '25 | $3M | -$87M | 0.0% | -3411.0% | -$67M | — | $357M |
| Sep '25 | $3M | -$82M | 0.0% | -3347.4% | -$27M | — | $113M |
| Jun '25 | $11M | -$77M | 0.0% | -736.8% | -$61M | — | $336M |
| Mar '25 | $22M | -$66M | 0.0% | -336.8% | -$80M | — | $90M |
| Dec '24 | $7M | -$71M | 0.0% | -1092.2% | -$63M | — | $120M |
| Sep '24 | $4M | -$62M | 0.0% | -1927.9% | -$50M | — | $111M |
| Jun '24 | $26M | -$42M | 0.0% | -198.5% | -$48M | — | $68M |
| Mar '24 | $10M | -$49M | 0.0% | -562.2% | -$47M | — | $94M |
| Dec '23 | $48M | -$14M | 0.0% | -40.3% | -$4M | — | $110M |
| Sep '23 | $5M | -$53M | 0.0% | -1216.3% | -$40M | — | $81M |
| Jun '23 | $17M | -$39M | 0.0% | -262.7% | -$46M | — | $52M |
| Mar '23 | $9M | -$41M | 0.0% | -478.8% | -$48M | — | $50M |
| Dec '22 | $16M | -$35M | 0.0% | -239.4% | -$40M | — | $68M |
| Sep '22 | $10M | -$43M | 0.0% | -469.9% | -$36M | — | $156M |
| Jun '22 | $12M | -$40M | 0.0% | -354.4% | -$40M | — | $77M |
| Mar '22 | $10M | -$37M | 0.0% | -383.8% | -$41M | — | $34M |
| Dec '21 | $15M | -$34M | 0.0% | -222.5% | -$39M | — | $48M |
| Sep '21 | $20M | -$29M | 0.0% | -140.8% | -$38M | — | $157M |
| Jun '21 | $19M | -$25M | 0.0% | -133.5% | -$31M | — | $85M |
Valuation over time
How the market has priced KYMR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 15.7× (Mar '23) to 30.7× (Jun '26).
- The price-to-sales ratio has risen from 52.1× (Mar '23) to 244.1× (Jun '26).
P/E
P/S
Frequently asked questions
Is KYMR growing its revenue and profit?
Over the past 5 years, Kymera Therapeutics, Inc.'s revenue has grown 2.9% per year. These are computed facts, not advice.
How much debt does KYMR have?
As of FY2025, Kymera Therapeutics, Inc. reported — of total debt against $357M of cash.
What is KYMR's profit margin?
In FY2025, gross margin was 0.0%, operating margin -891.1%, and net margin 794.0%.
What is KYMR's P/E ratio?
As of Jun '26, Kymera Therapeutics, Inc. traded at a price-to-earnings ratio of about 30.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.